Investment Info

Webcast ImageWebcast
Q3 2013 Urologix, Inc. Earnings Conference Call (Replay)
05/01/13 at 4:00 p.m. CT
Q3 2013 Urologix, Inc. Earnings Conference Call
Wednesday, May 1, 2013 4:00 p.m. CT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Urologix, Inc., based in Minneapolis, is the leading provider for in-office BPH therapy. The company develops, manufactures, markets and distributes minimally invasive medical products for BPH treatment. Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH.

Urologix' patented Cooled ThermoTherapy™ technology is creating effective treatment options for a wide range of patients with BPH. Cooled ThermoTherapy delivers precisely targeted microwave energy that heats and destroys enlarged prostatic tissue while unique cooling mechanisms protect surrounding healthy tissue and enhances patient comfort.

Prostiva® RF Therapy provides direct visualization with 360 degrees of precision which allows the urologist to treat the median and lateral lobe as well as asymmetrical prostates. This system is able to reach intraprostatic temperatures of 110°C allowing it to create a lesion in the tissue causing significant necrosis in just two minutes and 20 seconds. Experienced physicians report good patient tolerability with the utilization of a prostate block.

Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

¹Data on file at Urologix, Inc.

Stock Quote
ULGX (Common Stock)
ExchangeOTCQB (US Dollar)
Financial Status IndicatorN
Price$0.31
Change (%) Stock is Down 0.01 (3.13%)
Volume77,500
Data as of 06/18/13 3:33 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
Download Documentation 2012 Annual Report
Recent NewsMore >>
DateTitle 
06/05/13Urologix to Transfer From NASDAQ to the OTCQB Marketplace
MINNEAPOLIS, June 5, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has authorized the transfer of the Company's common stock from The NASDAQ Capital Market ("NASDAQ") to OTC Markets Group's OTCQB Marketplace ("OTCQB"). Urologix expects that its stock will begin trading on the OTCQB under the ticker symbol "ULGX" effective June 7, 2013. As of that date, investors and other interested parties will ... 
Printer Friendly Version
05/29/13Urologix In-Office BPH Therapy Featured on The Balancing Act on Lifetime Television
... 
Printer Friendly Version
05/02/13Urologix Brings Hands-On BPH Workshop to 2013 AUA Annual Meeting
... 
Printer Friendly Version
05/01/13Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual Guidance
Third Quarter Summary Third quarter revenue of $4.1 million Quarter-end cash balance of $5.1 million Guidance for fiscal year 2013 revenue reaffirmed at $16.0 million to $17.0 million MINNEAPOLIS, May 1, 2013 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office BPH therapy, today reported financial results for its fiscal year third quarter ended March 31, 2013. Third quarter fiscal year 2013 revenue totaled $4.1 million, down 6.3% seq... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Urologix, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.